Marie-Laure Santiago Raber

Company: Amal Therapeutics

Job title: Chief Scientific Officer

Seminars:

A Heterologous Prime-Boost Vaccination With a Peptide-Based Vaccine & Viral Vector Improves Antitumour Therapy in Preclinical Models. Maximise the Potential of In Vivo Studies to Validate a Platform Preclinically & Prepare for Regulatory Interactions 2:15 pm

Investigating regimen, combination and vaccine MoA supported by preclinical studies Harnessing preclinical models to study changes in the tumour microenvironment and T-cell function after vaccinationRead more

day: Day One